Biogen Idec's ELOCTATE and ALPROLIX Will Grow the Hemophilia Market, a ZoomRx Study Finds


Biogen Idec's ELOCTATE and ALPROLIX Will Grow the Hemophilia Market, a ZoomRx Study Finds

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Idec's (NASDAQ: BIIB) new hemophilia drugs, ELOCTATE (rFVIIIFc) and ALPROLIX (rFIXFc), are poised to capture a significant share of the hemophilia market and also grow the market steadily by increasing prophylactic treatment, a new market research study by ZoomRx reveals. ELOCTATE and ALPROLIX, indicated for hemophilia A and hemophilia B respectively, are long-acting therapies that will significantly improve the quality of life of patients by reducing the number of infusions that patients require to manage this chronic condition.

ZoomRx, a healthcare market research consultancy, conducted this study with over 150 hemophilia treating physicians during June and July of 2013. The study reveals that physicians who treat hemophilia perceive ELOCTATE and ALPROLIX to have similar efficacy and safety profiles as the existing therapies in the market, but expect them to perform better in terms of patient convenience. With improved convenience, physicians indicate that patients are more likely to switch to a prophylactic treatment regimen, where they use the drug regularly in a preventive manner instead of using the drug only when a bleed occurs. Patients using prophylactic treatment consume significantly larger unit volumes of the drug, hence contributing to market growth, the study notes.

ZoomRx's hemophilia commercial effectiveness study focuses on how hemophilia is currently being treated and the impact of new long-acting therapies on the US market. It includes individual reports for both hemophilia A and B markets and also provides access to an online business intelligence portal that contains all the quantitative and qualitative research data collected. The reports cover the following topics:

  • Current treatment trends

  • Current product perception

  • Unmet needs with current treatments

  • Awareness and knowledge of in-development therapies

  • Perception and anticipated use of Biogen Idec's hemophilia drugs

  • Barriers and drivers to the adoption of Biogen Idec's hemophilia drugs

Subsequent waves of this report will explore the evolving perception and use of Biogen Idec's therapies, progression of other long-acting therapies currently in development, and other key events in the hemophilia market.

For the latest on ZoomRx's coverage of the hemophilia market, contact or visit the ZoomRx website.

About ZoomRx:

ZoomRx is a privately-held, healthcare market research consultancy that specializes in primary and syndicated market research. ZoomRx tracking studies aim to deliver richer insights and higher ROI for their pharmaceutical and biotech clients through the use of innovative research methodologies and cutting-edge technology. ZoomRx's feature-rich mobile technology platform is customized for the healthcare industry and is capable of generating both quantitative and qualitative insights.

ZoomRx is headquartered in Cambridge, MA and has a branch office in Chennai, India. For more information, contact or visit

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Safe Harbor:

This press release contains opinions and forward looking statements that represent ZoomRx's interpretation and analysis of information generally available to the public or reported by physicians professionally screened for the subject matter. ZoomRx believes that the sources of information on which the material is based are reliable. ZoomRx has also applied their best professional judgment to the data obtained. However, actual results could differ materially from those expressed, projected or implied in these forward-looking statements. ZoomRx cautions readers not to place undue reliance on such statements. ZoomRx does not assume any liability for the accuracy, comprehensiveness, or use of the information presented.

Shane Becerra, 617-0401-2354
Marketing Manager

KEYWORDS: United States Asia Pacific North America Massachusetts India


The article Biogen Idec's ELOCTATE and ALPROLIX Will Grow the Hemophilia Market, a ZoomRx Study Finds originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Originally published